{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:56:21Z","timestamp":1789851381162,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T00:00:00Z","timestamp":1436140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Proliferation"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Adiponectin, a functional ligand of adiponectin receptor\u20101 (AdipoR1) and adiponectin receptor\u20102 (AdipoR2), has been found to be linked to risk of development of chronic myeloid leukaemia (<jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>). Imatinib, as its first\u2010line therapy, exhibits striking activity in both chronic and accelerated phases of the condition. However, numerous clinical trials have shown that many patients become refractory or experience relapses. Thus, development of new, hopefully effective Imatinib\u2010based treatment strategies, are still needed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Effects of recombinant adiponectin protein, in enhancing Imatinib anti\u2010tumour activities, in K562 and <jats:styled-content style=\"fixed-case\">MEG<\/jats:styled-content>\u201001 <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> cells, were examined <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Forty\u2010eight consecutive newly diagnosed adult patients with Bcr\u2010Abl\u2010positive <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>, in the early chronic phase (<jats:styled-content style=\"fixed-case\">ECP<\/jats:styled-content>), were enrolled in the study. Imatinib efficacy, plasma adiponectin levels and their correlations were analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data presented here indicate that adiponectin enhanced Imatinib efficacy <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Furthermore, this augmented effect was due to inhibition of Bcr\u2010Abl tyrosine kinase activity in an AdipoR1\u2010dependent way, while AdipoR2 was not involved. Most importantly, additional clinical data revealed that adiponectin plasma levels in <jats:styled-content style=\"fixed-case\">CML ECP<\/jats:styled-content> patients, correlated with Imatinib efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Adiponectin enhanced Imatinib anti\u2010tumour activity in human chronic myeloid leukaemia cells and its serum levels were associated with Imatinib efficacy, in early chronic phase patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cpr.12194","type":"journal-article","created":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T11:53:25Z","timestamp":1436183605000},"page":"486-496","source":"Crossref","is-referenced-by-count":2,"title":["Adiponectin enhances Imatinib anti\u2010tumour activity in human chronic myeloid leukaemia cells with serum levels associated with Imatinib efficacy in early chronic phase patients"],"prefix":"10.1111","volume":"48","author":[{"given":"Guangshan","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Pharmacy People's Hospital of Liaocheng Shandong 252000 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy People's Hospital of Liaocheng Shandong 252000 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology People's Hospital of Liaocheng Shandong 252000 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology People's Hospital of Liaocheng Shandong 252000 China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.NA0411"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/86.3.858S"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.10.004"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1530\/JME-12-0003"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.12.018"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.11.089"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(02)02305-5"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111501200"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206028"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.775"},{"key":"e_1_2_7_14_1","first-page":"100","article-title":"Inhibition of the abl protein\u2010tyrosine kinase in vitro and in vivo by a 2\u2010phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger E","year":"1996","journal-title":"Cancer Res."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5486.1938"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00979-3"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01705"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.04.068"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0076"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70379-0"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1723"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050473"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90438-0"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.11.1296"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.12.7.968"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2011-1015"}],"container-title":["Cell Proliferation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcpr.12194","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cpr.12194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:13:05Z","timestamp":1696331585000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cpr.12194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1111\/cpr.12194"],"URL":"https:\/\/doi.org\/10.1111\/cpr.12194","archive":["Portico"],"relation":{},"ISSN":["0960-7722","1365-2184"],"issn-type":[{"value":"0960-7722","type":"print"},{"value":"1365-2184","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,6]]}}}